ADC Therapeutics to Share New Data on LOTIS-7 Trial Evaluating ZYNLONTA + Glofitamab

ADC Therapeutics is preparing to reveal fresh clinical insights on its ongoing LOTIS-7 Phase 1b trial. The company will host a conference call and live webcast on December 3, 2025, at 8:00 a.m. EST.

The trial evaluates the safety and efficacy of ZYNLONTA®, the company’s flagship ADC, in combination with the bispecific antibody glofitamab (COLUMVI®) for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

What the Announcement Covers?

• Trial Status: The LOTIS-7 study is an open-label Phase 1b trial assessing this dual-agent approach in heavily pre-treated lymphoma patients.
• Accessing the Update: Participants can join through a guided registration link.
  A toll-free dial-in number (1-800-836-8184) is available for callers in North America and Canada. ADC Therapeutics recommends joining ten minutes early.
• Replay Details: A full webcast will be hosted in the Events and Presentations section of the company’s Investor page. An archived version will remain available for 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a global leader in antibody-drug conjugates. The company focuses on targeted therapies that deliver potent cytotoxics directly to cancer cells.

Key Assets

• ZYNLONTA (loncastuximab tesirine-lpyl)
  - A CD19-directed ADC.
  - Holds FDA accelerated approval.
  - Received conditional approval from the European Commission.
  - Indicated for r/r DLBCL after two or more lines of systemic therapy.
  - Being evaluated in combination regimens and earlier treatment settings.
• Next-Generation PSMA-Targeting ADC
  - Designed using a differentiated exatecan-based payload.
  - Uses a novel hydrophilic linker.
  - Undergoing IND-enabling activities.

Global Footprint

ADC Therapeutics operates from Lausanne (Biopôle), Switzerland, with teams in London and New Jersey. The company manages end-to-end capabilities spanning research, clinical development, manufacturing and commercialization.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!